
Novoic detects brain diseases early by analyzing a patient's speech to find subtle, disease-related vocal changes. The company builds in-house AI and deep learning models that analyze acoustic and linguistic features to decode complex speech alterations. Novoic is a digital biotech B2B company that provides its technology as clinical and research tools and APIs for healthcare and life‑science customers. Its platform targets early diagnostics and monitoring for neurological conditions by turning speech into objective digital biomarkers.

Novoic detects brain diseases early by analyzing a patient's speech to find subtle, disease-related vocal changes. The company builds in-house AI and deep learning models that analyze acoustic and linguistic features to decode complex speech alterations. Novoic is a digital biotech B2B company that provides its technology as clinical and research tools and APIs for healthcare and life‑science customers. Its platform targets early diagnostics and monitoring for neurological conditions by turning speech into objective digital biomarkers.
What they do: AI-based speech analysis to detect early neurological disease and produce speech-derived digital biomarkers
Flagship product: Storyteller — automated, browser-based speech cognitive testing (Automated Story Recall Task + AI analysis)
Clinical validation: Validated in biomarker-confirmed AMYPRED studies detecting early Alzheimer's-related changes
Founded: 2019 (London/Oxford roots)
Stage / funding: Seed (last disclosed round Jul 2020)
Early diagnostics and monitoring of neurological conditions using speech-derived digital biomarkers
2019
Biotechnology
Multiple investors reported including APEX Ventures, Entrepreneurs First, Plug and Play, Stanford Angels and Entrepreneurs
“Has participated investors experienced in fintech/health investment (Anthemis Exponential Ventures listed as lead and multiple early-stage investors listed)”